

CITATION REPORT

List of articles citing

**Management of hepatocellular carcinoma in Japan:
Consensus-Based Clinical Practice Guidelines
proposed by the Japan Society of Hepatology (JSH)
2010 updated version**

DOI: 10.1159/000327577

Digestive Diseases, 2011, 29, 339-64.

Source: <https://exaly.com/paper-pdf/50122366/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
685	Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. 2011 , 81 Suppl 1, 1-10		18
684	miR-146a suppresses the sensitivity to interferon- β in hepatocellular carcinoma cells. 2011 , 414, 675-80		59
683	Diagnostic imaging of hepatocellular carcinoma: recent progress. 2011 , 81 Suppl 1, 73-85		48
682	Adjuvant therapy after curative treatment for hepatocellular carcinoma. 2011 , 81 Suppl 1, 50-5		38
681	Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. <i>Digestive Diseases</i> , 2011 , 29, 289-302	3.2	30
680	Future treatment option for hepatocellular carcinoma: a focus on brivanib. <i>Digestive Diseases</i> , 2011 , 29, 316-20	3.2	9
679	Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. <i>Digestive Diseases</i> , 2011 , 29, 273-7	3.2	19
678	Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease. 2012 , 157, 302; author reply 303-4		2
677	Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2012 , 1, 22-40	9.1	53
676	Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imaging. <i>Liver Cancer</i> , 2012 , 1, 51-8	9.1	29
675	New paradigm for management of hepatocellular carcinoma by imaging. <i>Liver Cancer</i> , 2012 , 1, 94-109	9.1	34
674	Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance. <i>Liver Cancer</i> , 2012 , 1, 141-3	9.1	47
673	Clinical impact of ultrasound-related techniques on the diagnosis of focal liver lesions. <i>Liver Cancer</i> , 2012 , 1, 238-46	9.1	21
672	Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience. <i>Digestive Diseases</i> , 2012 , 30, 609-16	3.2	22
671	Invited commentary. 2012 , 32, 1995-8; discussion 1998		1
670	Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. 2012 , 157, 299-300; author reply 300		2
669	Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. 2012 , 41, 903-9		20

668	Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. 2012 , 157, 299; author reply 300		2
667	Screening for liver cancer: the rush to judgment. 2012 , 157, 300-1; author reply 301-2		2
666	Authors' Response. 2012 , 32, 1998-1998		
665	Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease. 2012 , 157, 302-3; author reply 303-4		1
664	Diagnostik und Früherkennung des hepatozellulären Karzinoms. 2012 , 7, 390-397		
663	An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. 2012 , 160, 146-52		49
662	Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. <i>Clinical Drug Investigation</i> , 2012 , 32 Suppl 2, 37-51	3.2	8
661	Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. 2012 , 57, 930-2		70
660	Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. 2012 , 56, 793-6		109
659	Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis. 2012 , 12, 376		12
658	Carcinome hépatocellulaire : pratiques occidentales et asiatiques. 2012 , 149, 345-350		
657	Hypovascular hepatic nodule showing hypointensity in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease: prediction of malignant transformation. 2012 , 81, 3072-8		37
656	Hepatocellular carcinoma: Western and Eastern surgeons' points of view. 2012 , 149, e302-6		6
655	Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®). <i>Clinical Drug Investigation</i> , 2012 , 32 Suppl 2, 25-35	3.2	2
654	Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. <i>Liver Cancer</i> , 2012 , 1, 190-200	9.1	72
653	Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. <i>Liver Cancer</i> , 2012 , 1, 62-70	9.1	88
652	Screening for Liver Cancer: The Rush to Judgment. 2012 , 157, 301		0
651	Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma. 2012 , 42, 226-32		14

650	Hepatocellular carcinoma: towards personalized medicine. 2012 , 103, 846-50			39
649	Cross-stage and combination treatment for Barcelona Clinic of Liver Cancer stage B (intermediate stage) hepatocellular carcinoma. 2012 , 27, 991-3			1
648	Treatment strategies for hepatocellular carcinoma in Japan. 2013 , 43, 44-50			18
647	Consensus report of the Fifth International Forum for Liver MRI. 2013 , 201, 97-107			35
646	Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. 2013 , 48, 951-65			30
645	The efficacy of nocturnal administration of branched-chain amino acid granules to improve quality of life in patients with cirrhosis. 2013 , 48, 269-76			30
644	Current chemotherapies for advanced hepatocellular carcinoma. 2013 , 6, 89-93			2
643	Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. 2013 , 58, 1459-76			35
642	Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. <i>Ultrasound in Medicine and Biology</i> , 2013 , 39, 187-210	3.5		503
641	A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 463-70	3.5		32
640	The size of the problem: clinical algorithms. <i>Digestive Diseases</i> , 2013 , 31, 95-103	3.2		5
639	Utility of adding Primovist magnetic resonance imaging to analysis of hepatocellular carcinoma by liver dynamic computed tomography. 2013 , 11, 187-92			19
638	A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. 2013 , 8, 239			23
637	Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase. 2014 , 119, 367-76			15
636	Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. 2013 , 24, 490-500			59
635	Hepatitis C-associated B-cell non-Hodgkin lymphomas: the emerging role of miRNA-26b. 2013 , 59, 1362-3			7
634	Treatment of hepatocellular carcinoma in Child-Pugh B patients. 2013 , 45, 852-8			25
633	Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. 2013 , 45, 712-23			128

632	Reply to: "non-invasive diagnosis of small nodules in cirrhosis". 2013 , 59, 1361-2		
631	Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. 2013 , 88, 530-49		131
630	The appropriate allocation of CEUS in the diagnostic algorithm of liver lesions: a debated issue. <i>Ultrasound in Medicine and Biology</i> , 2013 , 39, 183-5	3.5	4
629	Ultrasonography-Guided Radiofrequency Ablation in Hepatocellular Carcinoma: Current Status and Future Perspectives. 2013 , 21, 9-15		2
628	Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan. 2013 , 84 Suppl 1, 21-7		28
627	Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. 2013 , 7, 269-79		34
626	Early hepatocellular carcinoma: definition and diagnosis. <i>Liver Cancer</i> , 2013 , 2, 69-72	9.1	49
625	Imaging-based diagnostic systems for hepatocellular carcinoma. 2013 , 201, 41-55		57
624	Evidence of diagnostic enhancement pattern in hepatocellular carcinoma nodules \geq cm according to the AASLD/EASL revised criteria. 2013 , 38, 1245-53		12
623	Small hepatocellular carcinoma: current and future approaches. 2013 , 7, 805-12		11
622	Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. 2013 , 29, 946-50		194
621	Local ablation for hepatocellular carcinoma in taiwan. <i>Liver Cancer</i> , 2013 , 2, 73-83	9.1	69
620	Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. <i>Liver Cancer</i> , 2013 , 2, 31-9	9.1	79
619	Surgical strategy for liver cancers in the era of effective chemotherapy. <i>Liver Cancer</i> , 2013 , 2, 47-54	9.1	19
618	The appropriate allocation of CEUS in the diagnostic algorithm of liver lesions: a debated issue. 2013 , 34, 8-10		2
617	Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. 2013 , 34, 11-29		369
616	Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. 2012 , 32, 348-59		387
615	Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. 2013 , 24, 1786-1792		85

614	Ultrasonography fusion imaging system increases the chance of radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on conventional ultrasonography. 2013 , 84 Suppl 1, 44-50		22
613	Precision in liver surgery. 2013 , 33, 189-203		40
612	Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?. 2013 , 19, 8808-21		53
611	Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: ultrasonography, CT and MR imaging. 2013 , 84 Suppl 1, 58-63		21
610	Utility of computed tomography fusion imaging for the evaluation of the ablative margin of radiofrequency ablation for hepatocellular carcinoma and the correlation to local tumor progression. 2013 , 43, 950-8		27
609	Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. 2013 , 28, 530-6		67
608	Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013 , 9, 357-64	1.9	28
607	Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. 2013 , 33, 771-9		74
606	Response to Giannini et al. 2013 , 108, 1175		
605	Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. 2013 , 109, 1904-7		100
604	Supplementation of branched-chain amino acids maintains the serum albumin level in the course of hepatocellular carcinoma recurrence. 2013 , 230, 191-6		8
603	Chronic liver diseases and hepatocellular carcinoma: an update for 2013. <i>Digestive Diseases</i> , 2013 , 31, 405-7	3.2	1
602	Yttrium 90 radioembolization: the horizon is changing for patients with intermediate and advanced hepatocellular carcinoma. 2013 , 57, 1694-6		2
601	Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2013 , 6, 755-9	4.4	8
600	Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments. <i>Digestive Diseases</i> , 2013 , 31, 490-8	3.2	20
599	Recent advance of local ablation for hepatocellular carcinoma. 2013 , 56, 964		1
598	Factors associated with compliance with recommendations for liver cancer screening in Korea: a nationwide survey in Korea. 2013 , 8, e68315		10
597	Treatment for hepatocellular carcinoma in elderly patients: a literature review. 2013 , 4, 635-43		65

596	Anesthetic Considerations for Patients with Liver Disease. 2013 ,		6
595	Clinical utility of imaging for evaluation of hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2014 , 1, 101-8	5.3	
594	Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan. 2014 , 5, 499-509		25
593	Comparative analysis of Laparoscopic versus open surgical radiofrequency ablation for malignant liver tumors. 2014 , 18, 122-8		7
592	Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015 , 7, 261-9	3.4	12
591	Factors affecting screening for hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2014 , 13, 204-210	3.1	11
590	Epidemiology of HCC in Brazil: Incidence and risk factors in a ten-year cohort. <i>Annals of Hepatology</i> , 2014 , 13, 386-393	3.1	35
589	Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey. <i>Digestive Diseases</i> , 2014 , 32, 717-24	3.2	20
588	Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update. 2014 , 87 Suppl 1, 7-21		65
587	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. <i>Liver Cancer</i> , 2014 , 3, 458-68	9.1	394
586	2014 KLCSSG-NCC Korea Practice Guidelines for the management of hepatocellular carcinoma: HCC diagnostic algorithm. <i>Digestive Diseases</i> , 2014 , 32, 764-77	3.2	59
585	Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. 2014 , 87, 330-41		116
584	Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan. 2014 , 87 Suppl 1, 104-9		15
583	Comparison of hepatic arterial infusion chemotherapy and sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series. 2014 , 2, 1028-1034		2
582	Imaging techniques for the diagnosis of hepatocellular carcinoma and the evaluation of response to treatment. 2014 , 34, 398-414		10
581	Partial splenic embolization with transarterial chemoembolization in patients with hepatocellular carcinoma accompanied by thrombocytopenia. 2014 , 2014, 960628		3
580	Systematic evidence-based clinical practice guidelines are ushering in a new stage of standardized management of hepatocellular carcinoma in Japan. 2014 , 8, 64-70		7
579	Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. 2014 , 34, 415-26		52

578	Non-hypervascular hypointense nodules \geq 1 cm on the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging in cirrhotic livers. <i>Digestive Diseases</i> , 2014 , 32, 678-89	3.2	23
577	State of the art: hepatocellular carcinoma. 2014 , 10, 1-6		29
576	Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 899-909	3.5	4
575	Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. 2014 , 120, 229-37		51
574	Factors associated with early cancer-related death after curative hepatectomy for solitary small hepatocellular carcinoma without macroscopic vascular invasion. 2014 , 21, 142-7		7
573	Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B. 2014 , 29, 1699-705		21
572	Clinicopathology of recurrent hepatocellular carcinomas after radiofrequency ablation treated with salvage surgery. 2014 , 44, 1062-71		11
571	Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. 2014 , 29, 1722-7		12
570	Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. 2014 , 44, 149-58		31
569	Efficacy and long-term outcomes of radiofrequency ablation in the elderly with hepatocellular carcinoma. 2014 , 44, 1095-101		7
568	Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. 2014 , 34, 174-83		53
567	Consensus report from the 6th International Forum for liver MRI using gadoxetic acid. 2014 , 40, 516-29		33
566	Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. 2014 , 8, 71-6		105
565	Treatment strategies of intermediate-stage hepatocellular carcinomas in Japan (Barcelona Clinic Liver Cancer stage B). 2014 , 87 Suppl 1, 78-81		13
564	Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A single-center retrospective study. 2014 , 2, 279-87		22
563	Quality assurance in ultrasound screening for hepatocellular carcinoma using a standardized phantom and standard clinical images: a 3-year national investigation in Korea. 2014 , 33, 985-95		8
562	Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. 2014 , 87 Suppl 1, 22-31		137
561	Treatment of hepatocellular carcinoma. <i>Digestive Diseases</i> , 2014 , 32, 554-63	3.2	29

560	Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis. 2014 , 2, 393-398		40
559	Time trends of clinical characteristics in hepatocellular carcinoma patients with chronic hepatitis B virus infection: A field survey between 2000 and 2012. 2014 , 2, 927-934		5
558	Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. 2014 , 146, 1691-700.e3		425
557	Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. 2014 , 61, 583-8		103
556	Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. 2014 , 49, 932-40		33
555	High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter. 2014 , 44, 1900-5		20
554	Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. 2014 , 31, 475-82		20
553	Rare benign tumors of the liver: still rare?. 2014 , 45, 202-17		11
552	Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines. <i>Digestive Diseases</i> , 2014 , 32, 696-704	3.2	33
551	Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma. 2014 , 34, 1278-86		6
550	Understanding Liver Cancer. 2014 ,		1
549	Treatment of intermediate-stage hepatocellular carcinoma. 2014 , 11, 525-35		315
548	Hepatocellular carcinoma: diagnostic criteria by imaging techniques. 2014 , 28, 795-812		28
547	Prognosis of small hepatocellular nodules detected only at the hepatobiliary phase of Gd-EOB-DTPA-enhanced MR imaging as hypointensity in cirrhosis or chronic hepatitis. 2014 , 24, 2476-81		10
546	Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells. 2014 , 21 Suppl 4, S591-600		27
545	Imaging of Liver Tumors in Patients with Chronic Liver Disease. 2014 , 2, 1		2
544	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. 2014 , 46, 549-55		43
543	Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. 2014 , 4, S112-21		22

542	Treatment algorithms for managing hepatocellular carcinoma. 2014 , 4, S80-9		48
541	The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. 2014 , 4, S3-S26		38
540	Successful treatment of hepatocellular carcinoma with lung metastasis using hepatic and bronchial artery infusion chemotherapy. 2014 , 53, 2493-7		4
539	Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG)]in advanced cancer of the liver. 2014 , 87, 21-9		40
538	Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. 2014 , 260, 329-40		282
537	Clinical significance of early interventional therapy of branched-chain amino acid granules in patients with hepatocellular carcinoma: propensity score matching analysis. 2014 , 45, 1082-90		3
536	Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ. 2014 , 87 Suppl 1, 32-6		32
535	Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience. 2015 , 89 Suppl 2, 27-32		19
534	Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. 2015 , 45, 59-74		64
533	Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis. <i>Digestive Diseases</i> , 2015 , 33, 728-34	3.2	8
532	Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma. 2015 , 89 Suppl 2, 47-52		16
531	Radiation Therapy Is a Reasonable Option for Improving the Prognosis in Hepatocellular Carcinoma. 2015 , 237, 249-57		3
530	Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015 , 4, 253-62	9.1	130
529	Challenges of Clinical Research on Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2015 , 33, 780-90	3.2	3
528	Contrast-Enhanced Ultrasound for the Characterization of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Liver Cancer</i> , 2015 , 4, 241-52	9.1	54
527	Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?. 2015 , 35, 1862-71		44
526	Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis. 2015 , 30, 1412-9		15
525	Transarterial embolization for pediatric hepatocellular carcinoma with cardiac cirrhosis. 2015 , 57, 766-70		24

524	Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. <i>Medicine (United States)</i> , 2015 , 94, e396	1.8	85
523	2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. 2015 , 16, 465-522		143
522	Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. 2015 , 11, 1603-12		9
521	Hyponatremia in hepatocellular carcinoma complicating with cirrhosis. 2015 , 6, 482-9		9
520	Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis. 2015 , 6, 394-402		14
519	Current status and future of radiofrequency ablation for hepatocellular carcinoma. 2015 , 58, 542		2
518	Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. 2015 , 21, 5582-90		20
517	Quantitative Assessment of Tissue Perfusion in Hepatocellular Carcinoma Using Perflubutane Dynamic Contrast-Enhanced Ultrasonography: A Preliminary Study. <i>Diagnostics</i> , 2015 , 5, 210-8	3.8	5
516	Contrast Enhanced MRI in the Diagnosis of HCC. <i>Diagnostics</i> , 2015 , 5, 383-98	3.8	22
515	A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization. 2015 , 10, e0125244		30
514	Combined Application of Gadoteric Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis. 2015 , 10, e0144247		21
513	Contrast-Enhanced Ultrasound in the Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Controversy over the ASSLD Guideline. 2015 , 2015, 349172		16
512	Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients. 2015 , 2015, 608216		10
511	Current management of hepatocellular carcinoma: an Eastern perspective. 2015 , 21, 3826-42		39
510	Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. 2015 , 21, 3970-7		17
509	Biomarkers in HCV Infection. 2015 , 70, 131-96		1
508	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. 2015 , 9, 603-27		79
507	Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. 2015 , 15, 236		15

506	Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology. <i>Medicine (United States)</i> , 2015 , 94, e1772	1.8	19
505	Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. <i>Liver Cancer</i> , 2015 , 4, 263-73	9.1	21
504	Locoregional Therapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015 , 4, 163-4	9.1	46
503	General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan. <i>Digestive Diseases</i> , 2015 , 33, 765-70	3.2	172
502	An international comparison of stakeholder motivation to implement liver cancer control. 2015 , 30, 645-55		4
501	Evaluation of ART Scores for Repeated Transarterial Chemoembolization in Japanese Patients with Hepatocellular Carcinoma. 2015 , 89 Suppl 2, 4-10		18
500	Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. <i>Digestive Diseases</i> , 2015 , 33, 735-44	3.2	15
499	Proposal of the performance status combined Japan Integrated Staging system in hepatocellular carcinoma complicated with cirrhosis. 2015 , 46, 2371-9		8
498	Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. 2015 , 33, 1257-62		61
497	Contrast-enhanced ultrasound in liver cancer. 2015 , 2, 51-62		3
496	Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). <i>Liver Cancer</i> , 2015 , 4, 96-105	9.1	19
495	Prognosis and therapy for ruptured hepatocellular carcinoma: problems with staging and treatment strategy. 2015 , 84, 366-371		20
494	Implication of an extremely high preoperative alpha-fetoprotein value (>4,000 ng/mL) for the long-term outcomes of hepatectomy for resectable hepatocellular carcinoma. 2015 , 157, 223-30		2
493	Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. 2015 , 32, 432		12
492	New imaging techniques for liver diseases. 2015 , 62, 690-700		79
491	Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. 2015 , 62, 848-54		157
490	Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. 2015 , 50, 667-74		26
489	Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study. <i>International Journal of Clinical Oncology</i> , 2015 , 20, 745-54	4.2	8

488	Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. 2015 , 30, 1197-204	32
487	Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoteric acid). 2015 , 204, 498-509	61
486	Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. 2015 , 19, 309-23	73
485	Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument. 2015 , 47, 877-83	7
484	Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization. 2015 , 76, 449-457	12
483	Contrast-Enhanced Ultrasound of Focal Liver Lesions. 2015 , 205, W56-66	135
482	Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases. 2015 , 84, 1540-1545	14
481	Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan. 2015 , 33, 424-32	41
480	Imagiological Diagnosis of Gastrointestinal Diseases - Diagnostic Criteria of Hepatocellular Carcinoma. 2015 , 22, 153-160	7
479	Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. 2015 , 115, 211-6	88
478	Diagnosing Borderline Hepatic Nodules in Hepatocarcinogenesis: Imaging Performance. 2015 , 205, 10-21	30
477	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. 2015 , 47, 324-30	30
476	Intermediate-stage HCC--upfront resection can be feasible. 2015 , 12,	17
475	Value of gadoteric acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease. 2015 , 84, 555-62	8
474	The influence of histological differentiation grade on the outcome of liver resection for hepatocellular carcinomas 2 cm or smaller in size. 2015 , 39, 1134-41	28
473	Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. 2015 , 33, 729-39	53
472	Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma. 2015 , 8, 41-6	1
471	Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. 2015 , 110, 836-44; quiz 845	76

470	Hong Kong consensus recommendations on the management of hepatocellular carcinoma. <i>Liver Cancer</i> , 2015 , 4, 51-69	9.1	35
469	Nonsurgical multidisciplinary approach for recurrent hepatocellular carcinoma after surgical resection. 2015 , 2, 29-38		0
468	Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. <i>Liver Cancer</i> , 2015 , 4, 85-95	9.1	75
467	2014 KLCSCG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2015 , 9, 267-317	4.8	140
466	Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?. 2015 , 25, 2859-68		95
465	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , 2015 , 275, 698-707	20.5	99
464	Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. 2015 , 205, 764-73		24
463	CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. 2015 , 36, 132-9		86
462	Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. 2015 , 45, 837-43		16
461	Editorial: dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma--authors' reply. 2015 , 41, 1218-9		
460	Imaging in Patients with Cirrhosis: Current Evidence. 2015 , 53, 919-31		4
459	Recent Advances in Tumor Ablation for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015 , 4, 176-87	9.1	82
458	Contrast-enhanced ultrasound for the differentiation of small atypical hepatocellular carcinomas from dysplastic nodules in cirrhosis. 2015 , 47, 775-82		15
457	Dynamic tumor-tracking radiotherapy with real-time monitoring for liver tumors using a gimbal mounted linac. 2015 , 117, 496-500		21
456	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. 2015 , 16, 1344-54		553
455	State-of-the-art imaging of liver fibrosis and cirrhosis: A comprehensive review of current applications and future perspectives. 2015 , 2, 90-100		44
454	Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. <i>Clinical Drug Investigation</i> , 2015 , 35, 751-9	3.2	19
453	Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting. 2015 , 16, 143-51		11

452	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules. 2015 , 62, 150-5		28
451	Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. 2015 , 42, 305-14		37
450	Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. 2015 , 12, 10		26
449	Liver stiffness measurement for risk assessment of hepatocellular carcinoma. 2015 , 45, 523-32		17
448	LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. 2015 , 61, 1056-65		333
447	Imaging approach to hepatocellular carcinoma, cholangiocarcinoma, and metastatic colorectal cancer. 2015 , 24, 19-40		9
446	Cryoablation provides superior local control of primary hepatocellular carcinomas of >2 cm compared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox. 2015 , 22, 1294-300		38
445	New advances in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2016 , 8, 421-38	3-4	102
444	Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis. 2016 , 17,		16
443	Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration. <i>Journal of Hepatocellular Carcinoma</i> , 2017 , 4, 1-9	5-3	20
442	Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. 2016 , 22, 160-7		61
441	Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. <i>OncoTargets and Therapy</i> , 2016 , 9, 4239-46	4-4	11
440	IS RESECTION OF HEPATOCELLULAR CARCINOMA IN THE ERA OF LIVER TRANSPLANTATION WORTHWILE? A single center experience. 2016 , 53, 169-74		5
439	Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. 2016 , 22, 262-74		80
438	Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. 2016 , 20, 468-474		4
437	What determines treatment success and future perspectives?. 2016 , 92, 123-4		
436	Extremely elevated alpha-fetoprotein due to acute exacerbation of chronic hepatitis B without malignancy: a case report. 2016 , 10, 140		3
435	Assessment of Preoperative Liver Function in Patients with Hepatocellular Carcinoma - The Albumin-Indocyanine Green Evaluation (ALICE) Grade. 2016 , 11, e0159530		36

434	National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2016 , 5, 97-106	9.1	39
433	Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. <i>Annals of Hepatology</i> , 2016 , 15, 82-90	3.1	21
432	Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Matching Score Analysis. <i>Medicine (United States)</i> , 2016 , 95, e3015 ^{1.8}	1.8	63
431	Expression of Phosphorylated AMP-Activated Protein Kinase Predicts Response to Transarterial Chemoembolization in Postoperative Cases of Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2016 , 95, e2908	1.8	4
430	Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade. 2016 , 91, 153-61		32
429	Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study. 2016 , 46, 521-8		6
428	Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. 2016 , 46, 201-8		59
427	Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma. 2016 , 46, 312-9		25
426	Outcomes of laparoscopic hepatic resection versus percutaneous radiofrequency ablation for hepatocellular carcinoma located at the liver surface: A case-control study with propensity score matching. 2016 , 46, 565-74		17
425	Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. 2016 , 31, 1291-9		30
424	Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. <i>Liver Cancer</i> , 2016 , 5, 175-89	9.1	27
423	Optimal Follow-up of Patients with Viral Hepatitis Improves the Detection of Early-stage Hepatocellular Carcinoma and the Prognosis of Survival. 2016 , 55, 2749-2758		9
422	Surgical Resection for Hepatocellular Carcinoma with Cardiac Cirrhosis after the Fontan Procedure. 2016 , 55, 3265-3272		24
421	Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. 2016 , 6, 35050		14
420	Vascular phases in imaging and their role in focal liver lesions assessment. 2015 , 62, 299-326		14
419	The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma. 2016 , 61, 1572-81		6
418	Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. 2016 , 41, 963-9		57
417	Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. 2016 , 3, 119-136		7

416	Health economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Korea. 2016 , 19, 759-68		8
415	Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study. 2016 , 51, 144-52		22
414	Risk Factors for Early Recurrence of Single Lesion Hepatocellular Carcinoma After Curative Resection. 2016 , 40, 2466-71		28
413	Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. 2016 , 10, 883-892		24
412	The role of liver transplantation or resection for patients with early hepatocellular carcinoma. 2016 , 37, 4193-201		12
411	Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 Observations Detected at CT and MR Imaging. <i>Radiology</i> , 2016 , 281, 129-39	20.5	64
410	Liver Imaging Reporting and Data System: Review of Major Imaging Features. 2016 , 51, 292-300		5
409	Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. 2016 , 51, 1150-1160		36
408	Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy. 2016 , 41, 2161-2168		11
407	Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. 2016 , 15, 234-56		30
406	Role of dual energy spectral computed tomography in characterization of hepatocellular carcinoma: Initial experience from a tertiary liver care institute. 2016 , 3, 162-71		19
405	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. 2016 , 146, 511.e1-511.e22		1
404	Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. 2016 , 20, 2002-2009		22
403	Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. 2016 , 65, 1148-1154		83
402	Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease. 2016 , 31, 69-80		19
401	Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. 2016 , 36, 166-76		18
400	[Selective internal radioembolization in nonresectable hepatocellular carcinoma]. 2016 , 87, 956-963		3
399	Aberrant expression of B7-H4 may contribute to the development of hepatocellular carcinoma. 2016 , 14, 5015-5024		5

398	Contrast-Enhanced Ultrasound of Focal Liver Lesions. 2016 , 51, 334-357		5
397	Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors. <i>Digestive Diseases</i> , 2016 , 34, 714-730	3.2	7
396	Surveillance for hepatocellular carcinoma. 2016 , 30, 1001-1010		15
395	Prognostic Scoring System for radiofrequency ablation: Usefulness of Albumin-bilirubin (ALBI)-grade. 2016 , 57, 312-319		3
394	A case report of hepatocellular carcinoma adjacent to hepatic biloma successfully treated by stereotactic body radiation therapy. 2016 , 57, 17-26		
393	Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI. <i>Liver Cancer</i> , 2016 , 5, 67-87	9.1	56
392	A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. <i>Medicine (United States)</i> , 2016 , 95, e4832	1.8	6
391	The Effectiveness of Multiple Electrode Radiofrequency Ablation in Patients with Hepatocellular Carcinoma with Lesions More than 3 cm in Size and Barcelona Clinic Liver Cancer Stage A to B2. <i>Liver Cancer</i> , 2016 , 5, 8-20	9.1	42
390	Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization. 2016 , 36, 1516-24		1
389	Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. 2016 , 151, 846-53		64
388	Hyperthermic Oncology from Bench to Bedside. 2016 ,		3
387	The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis. 2016 , 5, 83-88		27
386	Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. <i>Liver Cancer</i> , 2016 , 5, 190-7	9.1	92
385	Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. 2016 , 64, 594-600		113
384	Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. 2016 , 65, 938-943		214
383	Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. 2016 , 11, 22		15
382	How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. 2016 , 43, 1337-45		29
381	Liver transplantation for advanced hepatocellular carcinoma in patients with Child-Pugh A and B. 2016 , 46, 248-54		15

380 A premature proposal for new liver cancer seromarkers. **2016**, 37, 4293-4

379 Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals. **2016**, 373, 45-56 52

378 Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. **2016**, 34, 255-60 31

377 Hepatocellular carcinoma detected by regular surveillance: Does timely confirmation of diagnosis matter?. **2016**, 48, 661-6 4

376 Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. **2016**, 31, 1031-6 139

375 A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients. **2016**, 27, 1288-1297 4

374 Effects of Cirrhosis on Short-term and Long-term Survival of Patients With Hepatitis B-related Hepatocellular Carcinoma. **2016**, 14, 887-895.e1 19

373 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. **2016**, 33, 1-28 211

372 [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. **2016**, 146, 511.e1-511.e22 36

371 TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. *Radiology*, **2016**, 279, 630-40 20.5 85

370 Pathobiologic Characteristics of Small Hepatocellular Carcinoma. **2016**, 11-24

369 Hepatocellular Carcinoma Screening and Surveillance: Practice Guidelines and Real-Life Practice. **2016**, 50, 120-33 38

368 Operative Techniques in Liver Resection. **2016**,

367 Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. *International Journal of Clinical Oncology*, **2016**, 21, 676-683 4.2 3

366 Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. **2016**, 64, 79-86 67

365 Thermal Ablation versus Surgical Resection for the Treatment of Stage T1 Hepatocellular Carcinoma in the Surveillance, Epidemiology, and End Results Database Population. **2017**, 28, 325-333 7

364 Imaging of hepatocellular carcinoma and image guided therapies - how we do it. **2017**, 17, 9 14

363 Understanding LI-RADS, Its Relationship to AASLD and OPTN, and the Challenges of Its Adoption. **2017**, 16, 72-80 3

362	Diagnosis of hepatocellular carcinoma: An update on international guidelines. 2017 , 98, 379-391	30
361	Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index. 2017 , 34, 1097-1108	8
360	Percutaneous radiofrequency ablation of hepatocellular carcinoma in cirrhosis: analysis of complications in a single centre over 20 years. 2017 , 90, 20160804	9
359	Importance of Screening for Esophagogastric Varices in Naïve Hepatocellular Carcinoma Patients within Milan Criteria: Indicator for Liver Transplantation. 2017 , 34, 429-435	1
358	Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial. 2017 , 17, 279	13
357	Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. 2017 , 66, 510-517	86
356	Review article: delivering precision oncology in intermediate-stage liver cancer. 2017 , 45, 1514-1523	19
355	Intrahepatic distant recurrence after radiofrequency ablation for hepatocellular carcinoma: precursor nodules on pre-procedural gadoteric acid-enhanced liver magnetic resonance imaging. 2017 , 58, 778-785	2
354	Subcentimeter hypervascular nodules with typical imaging findings of hepatocellular carcinoma on gadoteric acid-enhanced MRI: Outcomes of early treatment and watchful waiting. 2017 , 27, 4406-4414	9
353	Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. <i>Liver Cancer</i> , 2016 , 6, 16-26	9.1 81
352	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. 2017 , 11, 317-370	955
351	Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. 2017 , 8, 915-925	100
350	Focal lesions in cirrhosis: Not always HCC. 2017 , 93, 157-168	17
349	Clinical utility of bioimpedance analysis in liver cirrhosis. 2017 , 24, 409-416	21
348	Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. 2017 , 11, 292-299	5
347	EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. 2017 , 37, 1515-1525	61
346	Cirrhotic Liver. 2017 , 447-489	1
345	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. 2017 , 67, 173-183	106

344	MRI of Small Hepatocellular Carcinoma: Typical Features Are Less Frequent Below a Size Cutoff of 1.5 cm. 2017 , 208, 544-551	14
343	Preoperative platelet-to-lymphocyte ratio can predict recurrence beyond the Milan criteria after hepatectomy for patients with hepatocellular carcinoma. 2017 , 47, 991-999	18
342	Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma. 2017 , 47, 632-640	2
341	The role of imaging in the surveillance and diagnosis of hepatocellular cancer. 2017 , 61, 171-179	9
340	Screening and Surveillance of Hepatocellular Carcinoma: An Introduction to Ultrasound Liver Imaging Reporting and Data System. 2017 , 55, 1197-1209	20
339	Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. 2017 , 28, 1503-1511.e2	20
338	Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. 2017 , 24, 1073274817729244	18
337	Radiologically Undetected Hepatocellular Carcinoma in Patients Undergoing Liver Transplantation: An Immunohistochemical Correlation With LI-RADS Score. 2017 , 41, 1466-1472	1
336	Therapeutic significance and indications of pulmonary metastasectomy for hepatocellular carcinoma following liver resection. 2017 , 48, 23-31	9
335	Nomograms for prediction of long-term survival in elderly patients after partial hepatectomy for hepatocellular carcinoma. 2017 , 162, 1231-1240	7
334	Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma. 2017 , 141, 1011-1017	5
333	S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. 2017 , 2, 407-417	42
332	All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments. 2017 , 143, 2327-2339	5
331	Effect of psoas muscle mass after endoscopic therapy for patients with esophageal varices. <i>Medicine (United States)</i> , 2017 , 96, e6868	1.8 3
330	Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area. 2017 , 10, 529-536	17
329	Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. <i>Liver Cancer</i> , 2017 , 6, 360-374	9.1 44
328	Liver Imaging Reporting and Data System Classification of Hepatocellular Carcinoma: Implications for Clinical Management. 2017 , 01, 083-093	
327	Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument. 2017 , 67, 991-998	19

326	Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. 2017 , 13, 1893-1905	8
325	Effect of treatment support on preventing local recurrence of hepatocellular carcinoma directly adjacent to the diaphragm. 2017 , 7, 61-66	2
324	Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma. 2017 , 35, 254-261	2
323	Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial. 2017 , 17, 322	3
322	Presence of non-hypervascular hypointense nodules on Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. 2017 , 32, 908-915	12
321	Factors predicting outcomes of microwave ablation of small hepatocellular carcinoma. 2017 , 122, 81-87	8
320	A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score. 2017 , 32, 651-658	2
319	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 2017 , 37, 423-433	34
318	Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. 2017 , 33, 1-10	31
317	Prognostic significance of low skeletal muscle mass compared with protein-energy malnutrition in liver cirrhosis. 2017 , 47, 1042-1052	14
316	Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study. 2017 , 93 Suppl 1, 113-119	19
315	Magnetic resonance imaging performed with gadoxetate disodium for the diagnosis of hepatocellular carcinoma in cirrhotic and non-cirrhotic patients. 2017 ,	3
314	Diagnostic du carcinome hépatocellulaire : l'imagerie de contraste et les agents hépatospécifiques intravés dans les nouvelles recommandations internationales. 2017 , 1, S84-S97	
313	Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study. <i>OncoTargets and Therapy</i> , 2017 , 10, 2761-2768	4-4 19
312	Comparison of Prognostic Impact between the Child-Pugh Score and Skeletal Muscle Mass for Patients with Liver Cirrhosis. 2017 , 9,	8
311	Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. 2017 , 8, 152-161	24
310	Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay. 2017 , 13, 140-153	16
309	Impact of Radiofrequency Ablation-Induced Glisson's Capsule-Associated Complications in Patients with Hepatocellular Carcinoma. 2017 , 12, e0170153	12

308	The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images. 2017 , 12, e0174594		8
307	Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. 2017 , 13, 1383-1393		12
306	Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. 2017 , 17, 608		38
305	Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification. 2017 , 15, 156		13
304	Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. 2017 , 17, 902		31
303	Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma. 2017 , 8, 1988-1994		7
302	Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. <i>Oncotarget</i> , 2017 , 8, 33911-33921	3-3	50
301	Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. 2017 , 6, 387-396		43
300	Postoperative low hepatitis C virus load predicts long-term outcomes after hepatectomy for hepatocellular carcinoma. 2018 , 117, 902-911		3
299	Minimally invasive liver resection for hepatocellular carcinoma of patients with liver damage B: A propensity score-based analysis. 2018 , 48, 539-548		7
298	Personalized management of patients with very early hypovascular hepatocellular carcinoma. 2018 , 38, 415-416		
297	ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma. 2018 , 117, 912-921		27
296	Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. 2018 , 91, 20170436		5
295	Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable?. <i>Digestive Diseases</i> , 2018 , 36, 228-235	3-2	1
294	Is Emergency Transcatheter Hepatic Arterial Embolization Suitable for Spontaneously Ruptured Hepatocellular Carcinoma in Child-Pugh C Cirrhosis?. 2018 , 29, 404-412.e3		7
293	Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. 2018 , 41, 734-743		20
292	Privileged portal metastasis of hepatocellular carcinoma in light of the coevolution of a visceral portal system and liver in the chordate lineage: a search for therapeutic targets. 2018 , 23, 548-564		7
291	Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma: A meta-analysis. 2018 , 38, 1820-1831		11

290	Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study. 2018 , 54, 259-264		5
289	Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. <i>Radiology</i> , 2018 , 286, 29-48	20.5	162
288	Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization. 2018 , 41, 861-866		38
287	Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. 2018 , 43, 13-25		223
286	A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. 2018 , 67, 575-585		32
285	Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma. 2018 , 48, E98-E106		7
284	Post-traumatic rupture of a suprarenal metastasis of hepatocarcinoma. 2018 , 96, 126-128		
283	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. 2018 , 117, 381-403		58
282	Does the Pringle maneuver affect survival and recurrence following surgical resection for hepatocellular carcinoma? A western series of 441 patients. 2018 , 117, 198-206		16
281	Initial radiofrequency ablation failure for hepatocellular carcinoma: repeated radiofrequency ablation versus transarterial chemoembolisation. 2018 , 73, 216.e1-216.e8		6
280	US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. 2018 , 43, 41-55		47
279	Aggressive intrahepatic therapies for synchronous hepatocellular carcinoma with pulmonary metastasis. 2018 , 20, 729-739		6
278	Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. 2018 , 53, 281-290		25
277	Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus. 2018 , 24, 4527-4535		18
276	Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. 2018 , 9, 741-749		8
275	Efficacy of sequential sorafenib plus hepatic arterial infusion chemotherapy in patients with Barcelona Clinic Liver Cancer stage B and C hepatocellular carcinoma: a retrospective single-institution study. 2018 , 22, 165-171		4
274	Hepatocellular carcinoma: one world, one cancer-different guidelines?. 2018 , 7, 41-43		4
273	Clinical nurse specialist role in setting up a joint hepatocellular carcinoma clinic at a specialist liver unit. 2018 , 16, S20-S28		

272	Hepatectomy plus adjuvant transcatheter arterial chemoembolization improves the survival rate of patients with multicentric occurrence of hepatocellular carcinoma. 2018 , 16, 5882-5890		3
271	Laparoscopic liver resection for the patients with hepatocellular carcinoma and chronic liver disease. 2018 , 3, 41		6
270	Progression of Hepatic Hypovascular Nodules with Hypointensity in the Hepatobiliary Phase of Gd-EOB-DTPA-enhanced MRI in Hepatocellular Carcinoma Cases. 2018 , 57, 165-171		3
269	Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. 2018 , 53, 1575-1583		12
268	Validation of the albumin-indocyanine green evaluation model in patients with resected hepatocellular carcinoma and comparison with the albumin-bilirubin score. 2019 , 26, 51-57		8
267	Short-course carbon-ion radiotherapy for hepatocellular carcinoma: A multi-institutional retrospective study. 2018 , 38, 2239-2247		24
266	Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. <i>Radiology</i> , 2018 , 289, 816-830	20.5	293
265	Multiple antenna placement in microwave ablation assisted by a three-dimensional fusion image navigation system for hepatocellular carcinoma. 2019 , 35, 122-132		11
264	Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study. <i>Liver Cancer</i> , 2018 , 7, 323-334	9.1	5
263	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. 2018 , 38, 1624-1634		16
262	Did AFP-L3 save ultrasonography in community screening?. 2018 , 34, 583-587		2
261	Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. 2018 , 47, 585-602		17
260	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. 2018 , 48, 1118-1130		9
259	The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: A propensity score matching study. 2018 , 7, 4475-4484		13
258	Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma. 2018 , 164, 1014-1022		9
257	Post-Traumatic Rupture of a Suprarenal Metastasis of Hepatocarcinoma. 2018 , 96, 125-127		
256	Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. 2018 , 23, 235-242		18
255	Premalignant and Early Malignant Hepatocellular Lesions in Chronic Hepatitis/Cirrhosis. 2018 , 487-505		1

254	Liver volume-based prediction model stratifies risks for hepatocellular carcinoma in chronic hepatitis B patients on surveillance. 2018 , 13, e0190261		4
253	Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. 2019 , 39, 2214-2229		116
252	Hepatocellular Carcinoma. 2019 ,		1
251	Radiological Diagnosis and Characterization of HCC. 2019 , 71-92		6
250	Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam. 2019 , 26, 1073274819865269		4
249	Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma:A Propensity Score Matching Analysis. 2019 , 11, 9321-9330		8
248	The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019), Sapporo, Japan, August 29-31, 2019. <i>Liver Cancer</i> , 2019 , 8, 1-204	9.1	78
247	Transarterial chemoembolization with pirarubicin-eluting microspheres in patients with unresectable hepatocellular carcinoma: Preliminary results. 2019 , 2, 69-77		1
246	Significant Correlation Between Grip Strength and m2bpgi in Patients with Chronic Liver Diseases. 2019 , 8,		4
245	Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. 2019 , 8, 4200-4213		5
244	Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy. 2019 , 14, e0218136		8
243	Curative Loco-regional Therapies for Early Hepatocellular Carcinoma: Is Combination Effective?. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2019 , 73, 121-123	0.6	
242	Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000. 2019 , 33, e22921		7
241	A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma. 2019 , 77, 67-86		6
240	Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). 2019 , 36, 52		2
239	Transient increases in serum α -fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma. 2019 , 17, 3026-3034		4
238	Development of a Non-Coding-RNA-based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC. 2019 , 6, 1801885		14
237	Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma. 2019 , 8, 1530-1539		4

236	Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection. 2019 , 39, 163-177		24
235	A hypothesis on paradoxical privileged portal vein metastasis of hepatocellular carcinoma. Can organ evolution shed light on patterns of human pathology, and vice versa?. 2019 , 126, 109-128		1
234	Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios. 2019 , 71, 1132-1141		8
233	The application of contrast-enhanced ultrasound for the characterization of hepatic tumors: An assessment focusing on hepatocellular carcinoma. <i>Advances in Digestive Medicine</i> , 2019 , 6, 15-20	0.1	0
232	Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. 2019 , 14, e0214613		4
231	Treatment strategies for locally advanced hepatocellular carcinoma. 2019 , 4, 12		11
230	Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. 2019 , 57, 563-583		6
229	Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. 2019 , 28, 228-235		14
228	Hepatocellular Carcinoma: Diagnosis and Prognosis. 2019 , 693-702		0
227	Hepatocellular Carcinoma: Treatment. 2019 , 703-714		
226	Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity score-matching analysis. 2019 , 34, 1809-1816		9
225	Stereotactic radiofrequency ablation for hepatocellular carcinoma. 2019 , 4, 18-18		
224	Abstracts. 2019 , 39, 2420-2468		
223	Development And Validation Of A Simple Model For Detection Of Early Hepatocellular Carcinoma In A Liver Cirrhosis Cohort. 2019 , 11, 9379-9386		4
222	Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety. <i>Medicine (United States)</i> , 2019 , 98, e15314	1.8	19
221	Magnetic resonance imaging features predictive of an incomplete response to transarterial chemoembolization in patients with hepatocellular carcinoma: A STROBE-compliant study. <i>Medicine (United States)</i> , 2019 , 98, e15592	1.8	4
220	Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma. 2019 , 69, 1983-1994		77
219	TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. 2019 , 29, 1285-1292		15

218	SIUMB guidelines and recommendations for the correct use of ultrasound in the management of patients with focal liver disease. 2019 , 22, 41-51	16
217	Sorafenib: key lessons from over 10 years of experience. 2019 , 19, 177-189	46
216	TRIM29 prevents hepatocellular carcinoma progression by inhibiting Wnt/ β catenin signaling pathway. 2019 , 51, 68-77	14
215	Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy. 2019 , 96, 192-199	3
214	A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger. 2019 , 132, 230-235	19
213	Recent advances in medical management of hepatocellular carcinoma. 2019 , 49, 14-32	41
212	Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. 2019 , 70, 684-691	81
211	Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?. 2019 , 29, 1724-1732	53
210	Clinico-Psychosocial Factors Predicting Hepatocellular Carcinoma Related Knowledge Among Patients with Chronic Liver Disease. 2020 , 35, 937-945	0
209	Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma. 2020 , 24, 50-57	12
208	2019 Update of Indian National Association for Study of the Liver'Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. 2020 , 10, 43-80	24
207	Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography. 2020 , 18, 2091-2100.e7	13
206	Hepatic resection with thrombectomy in the treatment of hepatocellular carcinoma associated with macrovascular invasion. 2020 , 98, 9-17	2
205	Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. 2020 , 69, 1492-1501	164
204	Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis. 2020 , 2020, 5087643	10
203	Innovative Surgical Approaches for Locally Advanced Hepatic Malignancy. 2020 , 04, 046-052	
202	Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study. 2020 , 33, 567-575	18
201	Advances in the early diagnosis of hepatocellular carcinoma. 2020 , 7, 308-319	35

200	A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020 , 9, 367-377		10
199	Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. 2020 , 8, 1301		3
198	Diagnostic value of the Glutaryltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma. 2020 , 10, 13519		7
197	Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma. 2020 , 15, e0237370		7
196	Why Cannot BCLC 0- or A-Stage Patients Receive Curative Treatment?. 2020 , 7, 125-133		1
195	Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia. 2020 , 122, 1587-1594		4
194	Dexamethasone prevents TACE-induced adverse events: A meta-analysis. <i>Medicine (United States)</i> , 2020 , 99, e23191	1.8	2
193	Recent Updates of Transarterial Chemoembolization in Hepatocellular Carcinoma. 2020 , 21,		35
192	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. <i>Liver Cancer</i> , 2020 , 9, 245-260	9.1	63
191	A Novel Pre-treatment Model Predicting Risk of Developing Refractoriness to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma. 2020 , 11, 4589-4596		3
190	The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. 2020 , 30, 5650-5662		2
189	Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. 2020 , 8, 553		15
188	Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection. 2020 , 17, 83-87		8
187	Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2020 , 75, 147-156	0.6	1
186	Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. 2020 , 15, e0230005		5
185	Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin. 2020 , 27, 1073274820935843		3
184	Prognostic value of expanded liver transplantation criteria-the 5-5-500 rule-in patients with hepatic resection for intermediate-stage hepatocellular carcinoma. 2020 , 27, 682-689		1
183	Characteristics and risk differences of different tumor sizes on distant metastases of hepatocellular carcinoma: A retrospective cohort study in the SEER database. 2020 , 80, 94-100		4

182	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. 2020 , 72, 2206-2218		49
181	The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. 2020 , 15, e0228857		51
180	Hepatic Resection With Thrombectomy in the Treatment of Hepatocellular Carcinoma Associated With Macrovascular Invasion. 2020 , 98, 9-17		
179	Epidemiology and surveillance for hepatocellular carcinoma: New trends. 2020 , 72, 250-261		263
178	Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. 2020 , 43, 996-1005		13
177	ALBI versus child-pugh in predicting outcome of patients with HCC: A systematic review. 2020 , 14, 383-400		10
176	Hepatic resection versus transarterial chemoembolization in infiltrative hepatocellular carcinoma: A multicenter study. 2020 , 35, 2220-2228		0
175	Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events. <i>Cancers</i> , 2020 , 12,	6.6	18
174	Microwave ablation versus sorafenib for intermediate-stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. 2020 , 37, 384-391		2
173	Surgical resection of early stage hepatocellular carcinoma: balancing tumor biology with the host liver. 2021 , 10, 5		0
172	Fully laparoscopic thermo-ablation of liver malignancies with or without liver resection: tumor location is an independent local recurrence risk factor. 2021 , 35, 845-853		1
171	Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis. 2021 , 36, 302-310		1
170	Utility of cone unit liver resection for small hepatocellular carcinoma: a propensity score matched analysis. 2021 , 23, 739-745		1
169	Microscopic portal vein invasion is a powerful predictor of prognosis in patients with hepatocellular carcinoma who have undergone liver resection. 2021 , 123, 222-235		1
168	Six months as a cutoff time point to define early recurrence after liver resection of hepatocellular carcinoma based on post-recurrence survival. <i>Updates in Surgery</i> , 2021 , 73, 399-409	2.9	1
167	Successful Anatomic Resection of Tumor-Bearing Portal Territory Delays Long-Term Stage Progression of Hepatocellular Carcinoma. 2021 , 28, 844-853		7
166	Ideal Surgical Margin to Prevent Early Recurrence After Hepatic Resection for Hepatocellular Carcinoma. 2021 , 45, 1159-1167		5
165	A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus.. 2021 , 10, 782-795		1

164	Transarterial Chemoembolization Plus External Beam Radiotherapy. 2021 , 181-189		
163	Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma. 2021 , 27, 189-207		6
162	The Recent Development of the Surgical Treatment for Hepatocellular Carcinoma. 2021 , 11, 2023		1
161	Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. 2021 , 9, 237		0
160	Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy. 2021 , 10,		1
159	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	7
158	Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. <i>Liver Cancer</i> , 2021 , 10, 320-329	9.1	13
157	Liver resection in elderly patients with hepatocellular carcinoma: age does matter. <i>Updates in Surgery</i> , 2021 , 73, 1371-1380	2.9	1
156	Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know?. 2021 , 12, 31		7
155	Development of TACE Refractoriness Scores in Hepatocellular Carcinoma. 2021 , 8, 615133		1
154	Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021 , 10, 224-239	9.1	1
153	The value of PIVKA-II versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma. 2021 , 4, 77-81		0
152	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. <i>Liver Cancer</i> , 2021 , 10, 181-223	9.1	38
151	The Role of Protease-Activated Receptor 2 in Hepatocellular Carcinoma after Hepatectomy. 2021 , 57,		1
150	Critical appraisal of TNM versus HKU staging system for postoperative prognostic evaluation of hepatocellular carcinoma. 2021 , 9, 919		0
149	Non-contrast Magnetic Resonance Imaging versus the Multiphase Computed Tomography with Respect to the Asia-Pacific Clinical Practice Guidelines: A Diagnostic Performance Study for Liver Cancer. 2021 , 32, 318-326		1
148	Circulating Biomarkers for Early Diagnosis of Hepatocellular Carcinoma.		
147	Portal Vein Irradiation Stent Plus Chemoembolization versus External Radiotherapy Plus Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Retrospective Study. 2021 , 44, 1414-1422		2

146	Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021 , 22, 1731-1736	1.7	1
145	Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. 2021 , OP2100227		1
144	Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. 2021 , 2021, 6670367		3
143	MRI is the most commonly used imaging modality for HCC screening at a tertiary care transplant center. 2021 , 46, 5142-5151		1
142	Transjugular Intrahepatic Portosystemic Shunt Creation for the Prevention of Gastric Variceal Rebleeding in Patients with Hepatocellular Carcinoma: A Multicenter Retrospective Study. 2021 , 32, 963-969		3
141	Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. <i>Hepatology Communications</i> , 2021 , 5, 1972-1986	6	4
140	Hepatocellular Carcinoma: Diagnosis and Surveillance.		0
139	Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. <i>Cancers</i> , 2021 , 13,	6.6	0
138	Reducing the heterogeneity in hepatocellular carcinoma. A cluster analysis based on clinical variables in patients treated at a quaternary care hospital. 2021 ,		3
137	Reducing the heterogeneity in hepatocellular carcinoma. A cluster analysis based on clinical variables in patients treated at a quaternary care hospital. 2021 , 86, 356-362		
136	Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial. 2021 , 157, 373-382		1
135	A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion. 2021 , 46, 2839-2849		4
134	Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. 2020 , 7, 609322		17
133	Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. 2021 , 9, 55		1
132	The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. 2021 , 14,		6
131	Laboratory Tests in Liver Diseases. 2019 , 19-34		1
130	Quality assessment of clinical practice guidelines on the treatment of hepatocellular carcinoma or metastatic liver cancer. 2014 , 9, e103939		17
129	Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension. 2014 , 9, e108755		38

128	Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. 2015 , 10, e0138776	25
127	Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase. 2016 , 11, e0157299	10
126	Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. 2016 , 11, e0161303	6
125	Prognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma. 2016 , 11, e0163119	5
124	Hepatocellular Carcinoma and Liver Transplantation: State of the Art. 2014 , 2, 176-81	32
123	New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. 2017 , 5, 169-176	12
122	Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. 2017 , 5, 235-248	12
121	Intra- and interobserver reliability of gray scale/dynamic range evaluation of ultrasonography using a standardized phantom. 2014 , 33, 91-7	2
120	Hepatocellular carcinoma surveillance: Eastern and Western perspectives. 2019 , 38, 191-199	8
119	Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis. 2018 , 10, 765-771	12
118	An Image Fusion System for Estimating the Therapeutic Effects of Radiofrequency Ablation on Hepatocellular Carcinoma. 2017 , 51, 263-269	7
117	Tree-based classification system incorporating the HVTT-PVTT score for personalized management of hepatocellular carcinoma patients with macroscopic vascular invasion. 2019 , 11, 9544-9555	5
116	Prognostic significance of lymphovascular infiltration in overall survival of gastric cancer patients after surgery with curative intent. 2019 , 31, 785-796	6
115	Methotrexate-associated Lymphoproliferative Disorder in the Liver Resembling Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. 2020 , 59, 2255-2260	1
114	The Effect of New Therapeutic and Diagnostic Agents on the Prognosis of Hepatocellular Carcinoma in Japan [An Analysis of Data from the Kanagawa Cancer Registry. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017 , 18, 2471-2476	1.7 5
113	Tumor marker doubling time can be useful as a prognostic marker for hepatocellular carcinoma. 2014 , 55, 550-552	1
112	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2019 , 20, 1042-1113	96
111	Characterizing Computed Tomography-Detected Arterial Hyperenhancing-Only Lesions in Patients at Risk of Hepatocellular Carcinoma: Can Non-Contrast Magnetic Resonance Imaging Be Used for Sequential Imaging?. 2020 , 21, 280-289	5

110	Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions. 2013 , 19, 1-16	45
109	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. 2020 , 26, 155-162	21
108	Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients. 2019 , 25, 381-389	9
107	Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. 2012 , 18, 6005-17	36
106	Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. 2012 , 18, 6398-408	38
105	Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma. 2013 , 19, 6127-30	17
104	Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. 2013 , 19, 8357-65	17
103	Contrast-enhanced ultrasound: Improving the preoperative staging of hepatocellular carcinoma and guiding individual treatment. 2014 , 20, 12628-36	10
102	Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma. 2015 , 21, 94-101	17
101	Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates?. 2015 , 21, 8888-93	3
100	Liver resection for hepatocellular carcinoma using a microwave tissue coagulator: Experience of 1118 cases. 2015 , 21, 10400-8	9
99	Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas. 2015 , 21, 10604-8	15
98	Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma. 2019 , 25, 5515-5529	16
97	Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma. 2014 , 32, 14-22	25
96	Diagnosis, treatment and prognosis of hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus. 2020 , 20, 101	12
95	Transcatheter embolization therapy in liver cancer: an update of clinical evidences. 2015 , 27, 96-121	51
94	High-intensity focused ultrasound (HIFU) for the treatment of hepatocellular carcinoma: is it time to abandon standard ablative percutaneous treatments?. 2013 , 2, 184-7	8
93	Treatment Strategy for Recurrent Multiple Hepatocellular Carcinoma. 2013 , 04, 408-412	2

92	Role of Tyro3, Axl, and Mer Receptors and Their Ligands (Gas6, and Protein S) in Patients with Hepatocellular Carcinoma. 2017 , 08, 112-130		7
91	Management of hepatocellular carcinoma: Enlightening the gray zones. <i>World Journal of Hepatology</i> , 2013 , 5, 302-10	3.4	29
90	Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2014 , 6, 670-6	3.4	26
89	Update in management of hepatocellular carcinoma in Eastern population. <i>World Journal of Hepatology</i> , 2015 , 7, 1562-71	3.4	19
88	Biological features and biomarkers in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015 , 7, 2020-8	3.4	12
87	Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. <i>World Journal of Hepatology</i> , 2015 , 7, 2274-91	3.4	39
86	Diagnosis and treatment of hepatocellular carcinoma: An update. <i>World Journal of Hepatology</i> , 2015 , 7, 362-76	3.4	88
85	Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus. <i>World Journal of Hepatology</i> , 2017 , 9, 1296-1304	3.4	11
84	DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study. <i>Gut and Liver</i> , 2013 , 7, 89-95	4.8	17
83	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2019 , 13, 227-299	4.8	151
82	Liver transplantation and aging. <i>World Journal of Transplantation</i> , 2020 , 10, 256-266	2.3	2
81	Characteristics of liver cancer at Khmer-soviet Friendship Hospital in Phnom Penh, Cambodia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 35-9	1.7	7
80	Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 5541-7	1.7	14
79	Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 1233-1240	5.3	3
78	European Multicenter Study on Degradable Starch Microsphere TACE: The Digestible Way to Conquer HCC in Patients with High Tumor Burden. <i>Cancers</i> , 2021 , 13,	6.6	0
77	Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 1	3.5	1
76	Current Status of Hepatocellular Carcinoma Treatment in Japan. <i>Clinical Drug Investigation</i> , 2012 , 32, 37-51	3.2	1
75	Current Status of Hepatocellular Carcinoma Treatment in Japan. <i>Clinical Drug Investigation</i> , 2012 , 32, 25-35	3.2	2

74	A Case of Pathological Complete Response after Combination Chemotherapy by Sorafenib and Cisplatin Hepatic Arterial Infusion for an Advanced Hepatocellular Carcinoma. <i>Japanese Journal of Gastroenterological Surgery</i> , 2013 , 46, 915-923	0.1	
73	Impact of European Guidelines on CEUS. 2015 , 139-140		
72	Surgical Treatment of Hepatocellular Carcinoma Accompanied with Portal Vein Tumor Thrombus. 2016 , 133-151		
71	Combination with Hyperthermia and Chemotherapy: Liver Cancer. 2016 , 261-274		1
70	Effectiveness of Radiofrequency Ablation of Initial Recurrent Hepatocellular Carcinoma after Hepatectomy: Long-Term Results and Prognostic Factors. <i>Open Journal of Radiology</i> , 2017 , 07, 177-189	0.2	1
69	Gastroenterologie. 2017 , 185-264		
68	Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. <i>Oncotarget</i> , 2018 , 9, 21560-21568	3.3	5
67	Types of Segment-Oriented Hepatic Resection by the Glissonean Pedicle Approach. 2019 , 49-260		
66	Efficacy evaluation of the CEUS-LI-RADS-v2017 system in differential diagnosis of liver tumors. <i>Medical Visualization</i> , 2019 , 57-67	0.2	
65	FIB-4 Is a Potential Tool for Hepatocellular Carcinoma Risk Stratification in Ethnically Diverse Chronic Hepatitis B Patients When Using Specific Cutoff Values. <i>Hepatitis Monthly</i> , 2019 , In Press,	1.8	
64	Safety and effectiveness of new embolization microspheres SCBRM for intermediate-stage hepatocellular carcinoma: A feasibility study. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021 , 21, 339-345 ^{3,3}		
63	Value of surgical resection compared to transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis of hazard ratios from five observational studies. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2020 , 24, 243-251	1.5	0
62	Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients. <i>International Journal of Gastrointestinal Intervention</i> , 2021 , 10, 183-188	0.2	
61	Measuring HCC Tumor Size in MRI-The Sequence Matters!. <i>Diagnostics</i> , 2021 , 11,	3.8	1
60	AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis. <i>Medicine (United States)</i> , 2021 , 100, e27673	1.8	4
59	Hepatocellular Carcinoma. 2020 , 1-29		
58	Time-intensity Curve Analysis of Hepatocellular Carcinoma using Two Contrast-enhanced Ultrasound Methods: Contrast Pulse Sequencing and Contrast Harmonic Imaging. <i>Advanced Ultrasound in Diagnosis and Therapy</i> , 2020 , 4, 217	0.5	1
57	AFP-L3 as a Prognostic Predictor of Recurrence in Hepatoblastoma: A Pilot Study. <i>Journal of Pediatric Hematology/Oncology</i> , 2021 , 43, e76-e79	1.2	

56	Current status of multimodal & combination therapy for hepatocellular carcinoma. <i>Indian Journal of Medical Research</i> , 2012 , 136, 391-403	2.9	6
55	Current management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 153-61	0.7	70
54	A Simple Method to Avoid Bile Duct Injury during Percutaneous Radiofrequency Ablation Therapy for Hepatocellular Carcinoma. <i>Case Reports in Oncology</i> , 2020 , 13, 1337-1342	1	
53	Phenformin synergistically sensitizes liver cancer cells to sorafenib by downregulating CRAF/ERK and PI3K/AKT/mTOR pathways. <i>American Journal of Translational Research (discontinued)</i> , 2021 , 13, 7508 ² 7523 ¹		
52	Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021 , 11, 729764	5.3	4
51	Anatomical nonanatomical liver resection for solitary hepatocellular carcinoma: A systematic review and meta-analysis. <i>World Journal of Gastrointestinal Oncology</i> , 2021 , 13, 1833-1846	3.4	0
50	Prognostic factors in hepatocellular carcinoma patients with Child-Pugh A liver function after hepatectomy: Not related to the surgical approach. <i>Annals of Hepatology</i> , 2021 , 27, 100580	3.1	
49	Role of Tumor Biomarkers in the Surveillance of Hepatocellular Carcinoma. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2021 , 78, 284-288	0.6	
48	Potential of PALBI-T score as a prognostic model for hepatocellular carcinoma in alcoholic liver disease.. <i>JGH Open</i> , 2022 , 6, 36-43	1.8	
47	A Simple Method to Avoid Bile Duct Injury during Percutaneous Radiofrequency Ablation Therapy for Hepatocellular Carcinoma. <i>Case Reports in Oncology</i> , 2021 , 13, 1337-1342	1	0
46	Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience.. <i>Cancers</i> , 2022 , 14,	6.6	3
45	The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?. <i>International Journal of Biological Sciences</i> , 2022 , 18, 536-551	11.2	4
44	Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia.. <i>Integrative Cancer Therapies</i> , 2022 , 21, 15347354211073066	3	
43	Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.. <i>Radiology</i> , 2022 , 211545	20.5	3
42	Efficacy of Local-regional Treatment Plus Sorafenib in Intermediate-stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization. <i>Advances in Digestive Medicine</i> ,	0.1	
41	Curcumin Boosts Natural Killer Cell-Based Immunotherapy in Impeding Progression of Hepatocellular Carcinoma Through Androgen Receptor/UL16 Binding Protein-2 Signal. <i>Science of Advanced Materials</i> , 2022 , 14, 188-195	2.3	
40	Detection of hepatocellular carcinoma in a population at risk: iodine-enhanced multidetector CT and/or gadoxetic acid-enhanced 3.0 T MRI.. <i>BMJ Open</i> , 2022 , 12, e058461	3	
39	Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced hepatocellular carcinoma with macrovascular invasion.. <i>Updates in Surgery</i> , 2022 , 1	2.9	2

38	Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?. <i>Journal of Personalized Medicine</i> , 2022 , 12,	3.6	3
37	Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.. <i>BMC Gastroenterology</i> , 2021 , 21, 470	3	0
36	Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study.. <i>Liver Cancer</i> , 2022 , 11, 61-74	9.1	0
35	Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.. <i>Frontiers in Immunology</i> , 2022 , 13, 869993	8.4	0
34	Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with NAFLD.. <i>Hepatology Communications</i> , 2022 ,	6	
33	New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.. <i>International Journal of Clinical Oncology</i> , 2022 , 1	4.2	2
32	Indonesian consensus on systemic therapies for hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> ,	1.9	
31	Computer-Aided Color Parameter Imaging of Contrast-Enhanced Ultrasound Evaluates Hepatocellular Carcinoma Hemodynamic Features and Predicts Radiofrequency Ablation Outcome. <i>Ultrasound in Medicine and Biology</i> , 2022 ,	3.5	
30	Decision-Making Scoring System for the Repetition of Conventional Transarterial Chemoembolization in Patients with Inoperable Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2022 , Publish Ahead of Print,	4.2	
29	Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. <i>World Journal of Gastrointestinal Surgery</i> , 2022 , 14, 528-537	2.4	
28	Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review. <i>OncoTargets and Therapy</i> , Volume 15, 703-716	4.4	
27	Effects of Early TACE Refractoriness on Survival in Patients with Hepatocellular Carcinoma: A Real-World Study. <i>Journal of Hepatocellular Carcinoma</i> , Volume 9, 621-631	5.3	
26	Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE. 2022 , 22,		0
25	Transarterial Chemoembolization in Hepatocellular Carcinoma: A Binational Japanese-German Study. Volume 9, 695-705		
24	Current Imaging Diagnosis of Hepatocellular Carcinoma. 2022 , 14, 3997		2
23	Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A bi-institutional propensity-matched cohort study.		0
22	Should associating liver partition and portal vein ligation for staged hepatectomy be applied to hepatitis b virus-related hepatocellular carcinoma patients with cirrhosis? A multi-center study. 2022 ,		0
21	Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression. 2022 , 21, 153303382211313		0

- 20 A Conceptual Classification of Resectability for Hepatocellular Carcinoma. ○
- 19 Primary Neoplasms of the Liver. 1-16 ○
- 18 Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. **2022**, 21, 153303382211173 ○
- 17 DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study. **2022**, 22, ○
- 16 Effect of postoperative adjuvant chemotherapy on esophageal squamous cell carcinoma patients with lymphovascular invasion and without lymph node metastasis. ○
- 15 An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI. ○
- 14 Transarterial Chemoembolization Failure in Patients with Hepatocellular Carcinoma: Incidence, Manifestation and Risk Factors. **2022**, 102071 ○
- 13 Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. **2023**, 30, 1243-1254 ○
- 12 Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma. **2023**, 37, ○
- 11 The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD. **2023**, 15, 66 ○
- 10 Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis. 12, ○
- 9 The role of PIVKA-II in hepatocellular carcinoma surveillance in an Asian population. **2023**, 52, 108-110 ○
- 8 Ablative Therapy in Non-HCC Liver Malignancy. **2023**, 15, 1200 ○
- 7 An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians. **2023**, 11, 586 ○
- 6 Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma. **2023**, 21, ○
- 5 Breakthroughs in Hepatocellular Carcinoma Therapies. **2023**, ○
- 4 Molecular characterization of genes related with angiogenesis, cold- hot tumor, and tumor immunity interactions in patients with TACE resistance in hepatocellular carcinoma. ○
- 3 Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin. 29, 1359-1373 ○

- 2 Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma. **2023**, 13, ○
- 1 Development and Validation of a Model including Arterial Enhancement Fraction to Predict the Progression in HCC Patients Undergoing Chemoembolization. ○